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Abstract 
Background: Serum chromogranin A (CgA) is routinely used as a biomarker in patients with 
neuroendocrine neoplasms (NENs). Several conditions and comorbidities may be associated with 
falsely elevated CgA, often leading to extensive diagnostic evaluation, which may be costly and 
harmful.  The aim of this study was to analyze the effectiveness of acute octreotide suppression 
test (AOST) in differentiating falsely elevated serum CgA.  
Methods: Our prospective study enrolled 45 patients from two different patient cohorts: 1) 29 
patients with suspicion or presence of NEN (extensive work-up and subsequent biopsy 
confirmed 16 NENs); 2) 16 consecutive patients admitted via emergency department without 
NEN (nonNENs). AOST was performed after an overnight fast. Baseline CgA was measured, 
after which 0.25 mg of octreotide was administered subcutaneously. CgA was measured 3 hours 
and 6 hours after administration.  
Results: Baseline CgA were similar in NENs and nonNENs. At the end of AOST, CgA 
decreased by a median of 83.3% (41.0-127.4) in nonNENs and 13.8% (0.0-43.6) in NENs 
(P<0.001). In patients with increased baseline CgA, decrease in CgA at 6th hour by  <51.3% had 
90.0% sensitivity and 88.9% specificity in detecting NENs. In patients with normal baseline 
serum CgA, decrease in CgA at 3rd hour by <17.6% had 83.3% sensitivity and 81.8% specificity 
in detecting patients with NENs. The diagnostic accuracy of AOST in the entire study population 
was 86.7%.  
Conclusions: AOST is a promising tool to increase the diagnostic accuracy of serum CgA. 
Key words: octreotide; suppression; test; chromogranin A; diagnosis; neuroendocrine neoplasm 
Introduction 
Chromogranin A (CgA) is routinely used only in the diagnosis and follow-up of patients with 
neuroendocrine neoplasms (NENs)1. NEN tumor cells secrete CgA, which has a diagnostic, 
predictive and prognostic role in this population of patients1. However, increased serum CgA can 
be found in patients with sepsis2, acute exacerbation of rheumatoid arthritis3, inflammatory 
bowel disease4, various metastatic malignancies5, heart and renal failure67, complicated 
myocardial infarction8, arterial hypertension9 and chronic atrophic gastritis10. Moreover, the use 
of proton pump inhibitors (PPIs) may also increase CgA serum levels11. 
Due to its non-specific nature, the exact diagnostic accuracy of CgA as a screening method in 
detecting patients with NENs remains controversial. Sensitivity of CgA ranges from 53% to 
85%, while specificity ranges from 84% to 96% in detecting patients with NENs in the general 
population12. This greatly differs between studies, depending mainly on the control group. 
Studies focusing on the diagnostic accuracy of CgA may be distinguished to those which exclude 
or include subjects with interfering factors. Studies that used healthy blood donors had highest 
diagnostic accuracy of CgA in detecting NENs, while the diagnostic accuracy substantially 
decreased when control group constited of patients using PPI or patients with other malignant 
diseases1,12. Moreover, in a study by Marotta V et al. that included 42 subjects affected with 
NEN, 120 subjects affected with non-endocrine neoplasias and 100 non-neoplastic subjects 
affected with benign nodular goiter, serum CgA had no diagnostic value in detecting patients 
with NENs13. 
The role of acute octreotide suppression test (AOST) in predicting long-term disease control has 
been extensively studied in patients with acromegaly, but with conflicting results. The dose of 
octreotide used in AOST varied between 0.05 and 0.1 mg. AOST seemed useful in predicting 
response to long-acting somatostatin analogue if the nadir growth hormone concentrations were 
use to interpret the AOST, but it showed no predictive value when the test was interpreted as 
relative change in serum growth hormone levels14.    
So far, only three studies have analyzed the role of AOST as a prognostic factor in patients with 
NENs15–17. The most representative was a study by Massironi et al., which showed that the 
decrease in serum CgA >30% during AOST with 0.2 mg of subcutaneous octreotide, was 
associated with greater overall survival and more favorable response to long-term octreotide 
treatment17.   
Serum CgA is influenced by wide variety of both physiological and pathological factors. It is 
often hard to determine the etiology of increased CgA in real patient: a consequence of 
comorbidities or “autonomous” hypersecretion from NENs? Dynamic testing is the cornerstone 
of modern endocrinology designed to deal with diagnosis of diseases caused by hormone 
hypersecretion. Although it seems logical that the AOST might help in differentiating the cause 
of increased serum CgA, neither one study has analyzed the difference in response to AOST 
between patients with falsely increased serum CgA and patients with NENs. 
We hypothesized that patients without NENs (nonNENs) have more pronounced decrease in 
serum CgA during AOST, and that AOST is superior to single CgA measurement in detecting 
patients with NENs.    
 
Methods 
This prospective study included two different patient cohorts.  
The first cohort consisted of consecutive patients referred to our institution due to suspicion or 
presence of NEN (N=29). All these patients underwent computed tomography (CT) and/or 
magnetic resonance imaging (MRI) and 99mTc-Tektrotyd scintigraphy. 18F-fludeoxyglucose 
positron emission tomography (18F-FDG PET) was performed in 2 patients. CT protocols 
included early arterial phase sequences and MRI protocols included both contrast enhanced and 
diffusion-weighted sequences. After the following diagnostic work-up and subsequent biopsy, 
NEN was confirmed in 16 patients and the other 13 patients were labeled as controls.  
The second cohort included 16 randomly selected patients admitted via emergency department 
due to various diseases. AOST was performed within the last two days of hospitalization. 
Extensive aforementioned diagnostic work-up has not been performed in the second cohort, due 
to low incidence of NENs in general population and consequent low probability that some of 
these randomly selected patients from emergency department had NEN.   
Patients who underwent curative surgery and did not have radiological evidence of recurrence or 
metastases were excluded from the study.  
Patients with NENs were classified based on ENETS guidelines of 201218. Medical history was 
analyzed in details for nonNEN patients. Based on previous reports regarding comorbidities that 
may affect serum CgA levels, they were labeled with one of the following which was considered 
to have the highest impact on serum CgA: acute infection, malignant disease apart from NEN, 
autoimmune disease, other chronic noninfectious diseases (2 or more: diabetes mellitus, arterial 
hypertension, chronic obstructive pulmonary disease, chronic renal failure, chronic heart failure) 
and PPI use. 
AOST was performed after an overnight fast and all patients were required to fast during the test. 
Plasma CgA was measured at baseline, after which octreotide 250 μg was administered 
subcutaneously. In order to lower costs of the study, we have divided one ampule of Sandostatin 
0.5 mg and performed the test simultaneously in two different patients. Venous blood samples 
were drawn 3 and 6 h after octreotide administration. CgA level was measured via ELISA using 
a commercially available kit (Demeditec Diagnostics GmbH, Germany) [26]. Blood samples 
were collected by venipuncture into serum-separator tubes without anticoagulant. Serum was 
separated by centrifugation and immediately stored at −20 °C until analysis, which was 
performed as described in the manufacturer’s instructions. Normal range was considered to be 
12.5 – 100 μg/L, as provided by the manufacturer. Elevated serum CgA was considered > 100 
μg/L. 
The study was conducted according to the Declaration of Helsinki and approved by the ethics 
committee of the University Hospital Center Sisters of charity. All patients gave their written 
informed consent to the study. 
 
Statistical analyses 
Patient characteristics were analyzed with descriptive statistics and presented as a median and 
interquartile range.  Since the majority of parameters did not follow normal distribution we used 
nonparametric tests as follows: independent continuous variables were compared with Mann-
Whitney U test and categorical variables were compared using Fisher's exact test. Receiver 
operating characteristic (ROC) analysis was used to analyze the diagnostic accuracy of CgA at 
each point during AOST. The results of (ROC) analysis were presented with area under the curve 
(AUC), 95% confidence interval, sensitivity and specificity for each CgA cut-off. Two-tailed P 
values <0.05 were considered significant. Statistical analyses were performed by using SPSS 
Version 20.0 and MedCalc Version 14.8.1. 
Results 
There were no differences in demographic characteristics and serum CgA levels between 
nonNEN and NEN patients. Age and gender were not associated with plasma CgA levels or with 
the magnitude of change in plasma CgA during the AOST. NonNEN patients had more 
pronounced decrease in serum CgA (Table 1, Figure 1). Characteristics of patients with NENs 
are presented in table 2. A total of 7 patients were taking PPIs prior to AOST (5 patients 
admitted via emergency department and 2 patients with suspicion of NEN (the presence of NEN 
was excluded after work-up). Among patients taking PPIs, 5 had increased baseline serum CgA 
and 2 patients had normal CgA.  NonNEN patients had the following factors and comorbidities 
that might be associated with serum CgA: PPI use in 5(17.2%), acute infection in 5(17.2%), 
autoimmune diseases in 7(24.1%), other chronic noninfectious diseases in 8 (27.6%) patients and 
other malignant disease in 4 (13.8%) patients.  
Patients with increased baseline serum CgA had more pronounced decrease in serum CgA during 
AOST although it did not reach statistical significance [-74.4% (-129.73 - (-7.81) vs. -27.8% (-
59.18 – (-15.09), P=0.083]. However, due to substantial difference in recruitment of patients 
with increased baseline serum CgA and normal baseline serum CgA, these two groups were 
analyzed separately. Normal baseline serum CgA consisted of 17 patients (6 NEN patients), 
while increased baseline serum CgA consisted of 28 patients (10 NEN patients). The proportion 
of NEN patients was similar in both groups. The proportion of patients with G1 NENs was 
higher [4 (66.7%) vs. 1 (12.5%)] in the normal baseline serum CgA group, although it did not 
reach statistical significance. The proportion of patients with localized disease was similar in 
both groups (1 (20.0%) vs 1 (11.1%)). 
In current study population, single measurement of CgA did not have any diagnostic accuracy in 
detecting NENs (AUC 0.477, 95% CI 0.296 - 0.659, P = 0.803). 
In patients with increased baseline serum CgA, the decrease of serum CgA at 6th hour of AOST 
by <51.3% had a 90.0% sensitivity and 88.9% specificity in detecting patients with NEN (AUC 
0.906, 95% CI 0.790 - 1.000). There was only one falsely negative patient with localized G3 
rectal NEC and serum NSE of 110.3 ng/ml (normal range <15 ng/ml). There were two false 
positive patients, a 65 year-old male patient admitted due to diabetic ketoacidosis and sepsis and 
a 24 year-old female who was admitted due to increased serum CgA and nonspecific dermatitis. 
All 5 patients who were taking PPIs and had increased baseline CgA, had the decrease in serum 
CgA >51.3% [median 94.5% (78.8 – 143.4)].    
In patients with normal baseline serum CgA the decrease of serum CgA at 3rd hour of AOST by 
<17.6% had a 83.3% sensitivity and 81.8% specificity in detecting patients with NENs (AUC 
0.788, 95% CI 0.544 - 1.000). There was only one false negative patient with metastatic G2 
rectal NEN (Ki67 8%) who had features of G3 NEN with large necrotic liver metastases and a 
serum NSE of 28.5 ng/ml. There were two false positive patients admitted via emergency 
department due to pulmonary embolism and metastatic gastric adenocarcinoma (Figure 2b). Two 
patients with normal baseline CgA while taking PPIs, had the decrease in serum CgA by 50.7% 
and 33.8%, respectively. 
The diagnostic performance of AOST is presented in table 3. Overall, the diagnostic accuracy of 
AOST in the entire study population was 86.7%. In a subgroup analysis, there was a trend of 
higher diagnostic accuracy in patients with pancreatic NENs, as well as in patients with G1 and 
G2 NENs and patients with metastatic disease, but these differences were not statistically 
significant due to small sample size (Table 4).  
 
Discussion 
To the best of our knowledge, this is the first study which analyzed the diagnostic performance 
of AOST in detecting patients with NENs. We have shown that AOST has excellent diagnostic 
performance in patients with increased baseline plasma CgA. In these patients, the decrease in 
serum CgA 6 hours after octreotide administration for less than 51.3%, had 91% diagnostic 
accuracy in detecting patients with NEN. Surprisingly, our results suggest that AOST may have 
important role in patients with normal baseline serum CgA, since the decrease of serum CgA for 
<17.6% 3 hours after octreotide administration had 79% diagnostic accuracy in detecting patients 
with NEN. This means that AOST has excellent performance in detecting patients with falsely 
increased serum CgA, but might have important role in detecting patients with NENs and normal 
baseline serum CgA. The difference in response to AOST between NEN patients with normal 
and increased baseline serum CgA was observed by Kos-Kudla et al16. Their study included 32 
patients with gastroenteropancreatic and lung NETs and serum CgA was measured 30, 60, 90 
and 120 minutes after 0.1 mg octreotide injection. Patients with increased baseline serum CgA 
had significant decrease in serum CgA. On the other hand, serum CgA did not change in patients 
with baseline normal serum CgA. Interestingly, in patients with increased baseline serum CgA, 
25% of patients had a decrease in serum CgA >60% at the end of the test. A study by Massironi 
et al. included  38 patients with gastroenteropancreatic NENs and plasma CgA was measured 3 
and 6 hours after 0.2 mg octreotide injection, approximately 50% of all patients had the decrease 
in plasma CgA for >50%17. Findings from both of these studies greatly differ from our results, 
suggesting that our AOST would have too many false negative results. However, several 
methodological differences between these studies make such conclusions impossible. For 
instance, we used different laboratory technique for serum CgA measurement and therefore any 
comparisons in serum CgA during AOST and cut-off values with other studies are difficult19,20. 
Our AOST protocol was similar to one reported by Massironi et al17. However, participants in 
our study were required to fast during the test and not to take proton pump inhibitors prior to test, 
both of which has not been specified in the aforementioned study. This may be important since 
both feeding and proton pump inhibitors may influence serum CgA levels21,11. Moreover, 
patients with poorly differentiated tumors, large tumor burden and poor functional status were 
excluded from their study, which might be important when interpreting AOST results.    
Only two patients with NEN had false negative result of AOST (the decrease in serum CgA 
>51% and both had rectal NENs. One patient had localized G3 NEC (Ki67 90%) and profoundly 
increased serum NSE levels. We can hypothesize that mildly increased baseline serum CgA was 
not caused by autonomous tumor secretion, but rather with systemic response to highly 
malignant disease22,23. In this setting, one would expect to see pronounced decrease in serum 
CgA during AOST. The other patient had metastatic G2 rectal NET with tumor burden of >75%. 
Her baseline serum CgA was normal but serum NSE was also increased. Similar to previous 
case, we can speculate that serum CgA was not associated with autonomous tumor secretion, and 
hence, associated with profound decrease during AOST. Thus, we suggest that AOST may not 
be accurate in patients with G3 NEC and patients with increased NSE that suggest aggressive 
biology. However, further studies are needed to elucidate this issue.  
On the other hand, it is a bit difficult to explain false positive results of AOST. MRI of the 
abdomen and thorax and 99mTc-Tektrotyd scintigraphy failed to identify NEN in 24-year old 
female patient with paradoxical rise in serum CgA during AOST. We repeated AOST in this 
patient 6 months after the initial testing. During the last AOST her dermatitis-associated 
symptoms were still present and her baseline serum CgA increased to 748 ng/ml. However, it 
decreased to 202 ng/ml at the end of AOST, which suggests the absence of NEN (this data have 
not been added to current analysis).     
Several points need to be addressed when discussing the potential clinical utility of AOST. First 
of all, we must highlight that this is a proof-of-concept study and that our results need to be 
validated in a different cohort prior to its use in clinical practice. We would like to propose a few 
suggestions when planning future studies with AOST. Ideally, future studies should be 
multicentric and should include only patients with well-differentiated NENs. Patients with poorly 
differentiated morphology and increased serum NSE or other tumor markers should be excluded, 
because our data suggests that these patients do not exhibit autonomous CgA secretion 
associated with NEN, leading to increased rate of false negative results. Moreover, AOST should 
be repeated in each patient with different octreotide dose (0.1 mg and 0.5 mg), in order to find 
the dose which provides the highest sensitivity and specificity of AOST. We suggest to measure 
serum CgA at both third and sixth hour of the test, due to significant difference in diagnostic 
performance at each time point in regard to baseline serum CgA concentration. Finally, AOST 
should be performed with different assays for CgA measurement, before it’s wider use in 
everyday clinical practice.   
In conclusion, our pilot study suggests that AOST is a safe and accurate method which may 
substantially improve the role of CgA as a screening tool for detecting NENs. In patients with 
increased baseline serum CgA, the decrease of serum CgA at 6th hour of AOST by <51.3% had 
91% diagnostic accuracy, while the decrease of serum CgA at 3rd hour of AOST by <17.6% had 
79% diagnostic accuracy in patients with normal baseline serum CgA. Hence, we can conclude 
that patients with NEN have less pronounced decrease in serum CgA during the AOST. Further 
validation studies are needed in order to implement this test in everyday clinical practice. 
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Table 1. The difference in demographic characteristics and serum chromogranin A levels during 
the acute octreotide suppression test between controls (nonNEN) and patients with 
neuroendocrine neoplasms 
 
 
 
 
nonNEN 
N=29 
NEN 
N=16 
P 
Age (years) 64.0 (56.0 – 74.5) 54.5 (47.0 – 69.0) 0.090 
Male (%) 14 (48.3) 11 (68.8) 0.224 
Baseline CgA increased (%) 18 (62.1) 10 (62.5) 1.000 
Baseline CgA (ng/ml) 169 (61 – 385) 126 (75 – 330) 0.803 
CgA 3rd  hour (ng/ml) 132 (45 – 265) 103 (64 – 267) 0.713 
CgA 6th  hour (ng/ml) 96 (36 – 201) 119 (55 – 233) 0.361 
Change (CgA 6h – CgA 0) % -83.3 (-127.4 – (-41.0)) -13.8 (-43.6 – 0.0) <0.001 
Change (CgA 3h – CgA 0) % -33.3 (-66.7 – (-19.6)) -9.2 (-27.3 – 6.2) 0.010 
Change (CgA 6h – CgA 3h) % -25.8 (-44.3 – (-14.6)) -6.4 (-23.1 – 3.0) 0.011 
Table 2. Characteristics of patients with neuroendocrine neoplasms 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Characteristic n (%) 
Primary tumor site   
Midgut and hindgut 
carcinoids 
9 (56.3) 
Pancreatic NENs 4 (25.0) 
Lung 1 (6.3) 
Pheochromocytoma 2 (12.5) 
WHO tumor grade   
1 7 (43.8) 
2 7 (43.8) 
3 2 (12.5) 
Tumor spread   
Localized disease 4 (25.0) 
Locoregional metastases 1 (6.3) 
Distant metastases 1 (6.3) 
Locoregional + distant 10 (62.5) 
Functional NEN 8 (50.0) 
Table 3. Diagnostic performance of change in serum CgA during acute octreotide suppression 
test. 
 AUC 95% CI for AUC P Cut-off 
(%) 
Sensitivity 
(%) 
Specificity 
(%) 
Increased baseline CgA        
Change (CgA 6h – CgA 0) .906 .790 1.000 .000 -51.3 90.0 .111 
Change (CgA 3h – CgA 0) .733 .543 .924 .044 -31.7 80.0 .278 
Change (CgA 6h – CgA 3h) .917 .812 1.000 .000 -11.6 80.0 .056 
Normal baseline CgA        
Change (CgA 6h – CgA 0) .697 .436 .958 .191 -34.4 66.7 .455 
Change (CgA 3h – CgA 0) .788 .544 1.000 .056 -17.6 83.3 .182 
Change (CgA 6h – CgA 3h) .470 .114 .826 .841 -6.4 50.0 .364 
Entire study population        
Change (CgA 6h – CgA 0) .832 .712 .952 .000 -51.5 93.8 .276 
Change (CgA 3h – CgA 0) .735 .587 .883 .010 -31.7 81.3 .379 
Change (CgA 6h – CgA 3h) .731 .565 .896 .011 -12.3 68.8 .241 
 
 
  
Table 4. Subgroup analysis showing diagnostic performance of AOST in different cohorts of 
patients with NEN (AOST was defined positive if patients with normal baseline serum CgA had 
the decrease of serum CgA at 3rd hour by >17.6% and if patients with increased baseline serum 
CgA had the decrease at 6th hour by >51.3%) 
 AOST negative AOST positive P 
Grade n(%)   0.192 
1 0 (0.0) 5 (100.0)  
2 1 (11.1) 8 (88.9)  
3 1 (50.0) 1 (50.0)  
Primary tumor n(%)   0.383 
Pancreas 0 (0.0) 4 (100.0)  
Other 2 (16.7) 
 
10 (83.3) 
 
 
Functionality n(%)   1.000 
Nonfunctional 1 (12.5) 7 (87.5)  
Functional 1 (12.5) 7 (87.5)  
Stage n(%)    
Localized 1 (25.0) 3 (75.0) 0.383 
Metastatic 
1 (8.3) 11 (91.7) 
 
 
 
  
Figure 1. Flowchart of the study population 
 
 
 
  
Figure 2. The difference in serum chromogranin A during acute octreotide suppression test 
between patients with neuroendocrine neoplasm and controls; in patients with increased baseline 
serum CgA (a) and normal baseline serum CgA (b) presented with box-plot graph; in patients 
with increased baseline serum CgA (c) and normal baseline serum CgA (d) presented with dot-
line diagram for each patient. 
 
 
  
    
Figure 3. The difference in change of serum chromogranin A during acute octreotide 
suppression test between controls and patients with NEN; in patients with increased baseline 
serum chromogranin A (a) and normal baseline serum chromogranin A levels (b)  
 
 
